1-3 of 3
Leonard Klein, MD
Close
Sort by
Journal Articles

Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Jeff P. Sharman, MD, Leonard Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Michael J. Hawkins, MD, Julie A Di Paolo, PhD, Jing Hu, Ph.D, Anita Reddy, PhD, Feng Jin, PhD, Flordeliza Melchor-Khan, BS, Christopher A. Yasenchak, MD
Journal: Blood
Blood (2013) 122 (21): 1634.
https://doi.org/10.1182/blood.V122.21.1634.1634
Published: 2013
Journal Articles

A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma

James R. Berenson, MD, Leonard Klein, MD, Robert M. Rifkin, MD, Priti Patel, MD, MS, Sandra Dixon, MS, Ying Ou, PhD, Alan Cartmell, MD
Journal: Blood
Blood (2013) 122 (21): 1934.
https://doi.org/10.1182/blood.V122.21.1934.1934
Published: 2013
Journal Articles

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard Klein, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD
Journal: Blood
Blood (2013) 122 (21): 3218.
https://doi.org/10.1182/blood.V122.21.3218.3218
Published: 2013